Non-Squamous Non-Small Cell Lung Cancer Completed Phase 3 Trials for Erlotinib (DB00530)

Also known as: Non-squamous Non-small Cell Lung Cancer

IndicationStatusPhase
DBCOND0036730 (Non-Squamous Non-Small Cell Lung Cancer)Completed3
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT01667562A Study of Erlotinib in Participants With Locally Advanced or Metastatic Non-Small Cell Lung CancerTreatment
NCT01456325A Study of Onartuzumab (MetMAb) in Combination With Tarceva (Erlotinib) in Participants With Met Diagnostic-Positive Non-Small Cell Lung Cancer Who Have Received Chemotherapy For Advanced or Metastatic Disease (MetLung)Treatment
NCT01328951A Study of First-line Maintenance Erlotinib Versus Erlotinib at Disease Progression in Participants With Advanced Non-Small Cell Lung Cancer (NSCLC) Who Have Not Progressed Following Platinum-Based ChemotherapyTreatment
NCT01351415A Study of Bevacizumab in Combination With Standard of Care Treatment in Participants With Advanced Non-squamous Non-small Cell Lung Cancer (NSCLC)Treatment
NCT00883779A Study of Tarceva (Erlotinib) or Placebo in Combination With Platinum-Based Therapy as First Line Treatment in Patients With Advanced or Recurrent Non-Small Cell Lung CancerTreatment
NCT01887886A Study of Onartuzumab in Combination With Erlotinib in Patients With MET-Positive Stage IIIB or IV Non-Small Cell Lung Cancer Carrying an Activating Epidermal Growth Factor Receptor (EGFR) MutationTreatment